BioBehavioral Diagnostics Completes First Close of $10M Series B Financing

BioBehavioral Diagnostics (BioBDx), a Plymouth Meeting and Westford, MA-based company which manufactures and markets a tool that aids in the objective and accurate assessment of attention-deficit hyperactivity disorder (ADHD), announced the first close of a $10m Series B financing.

Sevin Rosen and Tullis Dickerson led the round.

The funds will enable the company to expand sales and marketing activities as well as to execute additional clinical work for its Quotient ADHD System, which is currently available in 20 states.
Founded in 2006, BioBehavioral Diagnostics aims to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine.

Join the discussion